Oruka Therapeutics insider plans $6.9M stock sale

Oruka Therapeutics, Inc. (ORKA) received a notice that Lawrence Klein intends to sell Oruka common stock under Rule 144.

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. (ORKA) received a notice that Lawrence Klein intends to sell Oruka common stock under Rule 144. The planned transaction involves up to 75,000 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or about 09/01/2026, with the shares to be acquired via exercise of stock options for cash. The notice also reports that Klein sold 1,729 shares of Oruka common stock on 06/15/2026 during the prior three months.

Key Figures

Shares to be sold: 75,000 shares of common stock Proposed aggregate sale price: $6,946,500.00 Prior 3-month shares sold: 1,729 shares of common stock +2 more

5 metrics

Shares to be sold 75,000 shares of common stock Planned Rule 144 sale dated 09/01/2026

Proposed aggregate sale price $6,946,500.00 For 75,000 shares of Oruka Therapeutics common stock

Prior 3-month shares sold 1,729 shares of common stock Sale by Lawrence Klein on 06/15/2026

Proceeds from prior 3‑month sale $120,494.01 Sale of 1,729 shares on 06/15/2026

Planned transaction date 09/01/2026 Date listed for the Rule 144 sale and option exercise

Key Terms

Rule 144, Securities To Be Sold, Exercise of Stock Options

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Securities To Be Sold financial

"144: Securities To Be Sold Common | 09/01/2026 | Exercise of Stock Options"

Exercise of Stock Options financial

"Common | 09/01/2026 | Exercise of Stock Options | Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Oruka Therapeutics, Inc. (ORKA)?

The filing discloses that Lawrence Klein plans to sell 75,000 shares of Oruka Therapeutics common stock under Rule 144, with the shares to be obtained by exercising stock options for cash and sold through Morgan Stanley Smith Barney LLC on or about 09/01/2026.

How many ORKA shares does Lawrence Klein plan to sell and when?

Lawrence Klein plans to sell 75,000 shares of Oruka Therapeutics common stock, with the transaction dated 09/01/2026. The shares are indicated as being sold under Rule 144 following an exercise of stock options for cash.

What was the proposed aggregate value of the planned ORKA share sale?

The notice lists a proposed aggregate value of $6,946,500.00 for the 75,000 shares of Oruka Therapeutics common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services in the Rule 144 transaction dated 09/01/2026.

Were any ORKA shares sold by Lawrence Klein in the prior three months?

Yes. The filing reports that Lawrence Klein sold 1,729 shares of Oruka Therapeutics common stock on 06/15/2026, with total proceeds of $120,494.01, during the three months preceding the planned Rule 144 sale.

Through which broker will the planned ORKA Rule 144 shares be sold?

The planned Rule 144 sale of 75,000 shares of Oruka Therapeutics common stock is listed as being effected through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:49 PM EDT Accepted by SEC EDGAR 09/01/2026 - 04:48 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001762583
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Oruka Therapeutics, Inc.
SEC File Number	000-22873
Address of Issuer	855 Oak Grove Avenue Suite 100 Menlo Park CALIFORNIA 94025
Phone	6506067910
Name of Person for Whose Account the Securities are To Be Sold	LAWRENCE KLEIN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	75000	6946500.00	66209699	09/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2026	Exercise of Stock Options	Issuer			75000	09/01/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
LAWRENCE KLEIN 855 Oak Grove Avenue Suite 100 Menlo Park CA 94025	Common	06/15/2026	1729	120494.01

144: Remarks and Signature

Remarks
Date of Notice	09/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/14/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Lawrence Klein
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)